Pbli

[STOCKMAN]

PLBI, Keep this one on your radar list. News came out after the close yesterday and this morning had some nice prebuys. This is going to have some nice volume and some nice gains today. Good news make this one fly. This afternoon this is going to explode. Take a position while the price is still low. Good luck here is the latest news..

SOSUA BAY, Dominican Republic, May 11, 2010 (GLOBE NEWSWIRE) -- Proton Laboratories, Inc. (Pink Sheets:PLBI - News) announced today that following its success in attaining exclusive rights for RNL Bio Company Ltd's licenses, technology and equipment which allows PLBI's wholly owned subsidiary, RegenoBody, S.A. to treat anyone within the Caribbean, Central and/or South America, that the laboratory needed to perform the work is being designed by RNL Bio for shipment to the RegenoBody facility in the Dominican Republic. The laboratory will be designed according to the specifications required of RNL Bio in Korea so that it can duplicate the success of RNL Bio in regenerating human stem cells.


The initial concept of bringing what was once stereotyped as a controversial treatment to this hemisphere was based upon more than a year of research and the actual treatment and successful results of PLBI's President, Armando Casciati. After Mr. Casciati's treatment, he acquired the majority control of PLBI.pk, in an effort to accelerate the process of bringing stem cell technology to the Western Hemisphere.


Mr. Casciati stated, "Entrepreneurs typically look merely for profit opportunities. I am proud to have found such an incredible life opportunity which will help serve the public with some of the latest technological advances in medical history. I believe our alliance with RNL Bio Company will prove to be a life changing opportunity for our clients, as it has been for me."


RNL Bio Company LTD is considered a leader in stem cell technology with a wealth of treatments. After years of investment and research, RNL has developed technology ranging from cosmetic and arthritic needs to spinal cord injury and cancer treatments.


Korean FDA approved RNL's human clinical study to treat patients with spinal cord injury using 'RNL-Astrostem' that is based on fat derived adult stem cells.


In early 2009, RNL Bio publicly presented its three years' preclinical trial results showing a perfect safety profile and remarkable efficacy potential. RNL was approved by the Korean government to begin phase I human trial using these adult stem cells and we believe it is the world's first trial to treat spinal cord injury with adult stem cells derived from a patients' own fat tissue.


Since the Korean FDA approval, RNL Bio has progressively increased the utility of its RNL-Astrostem technology. RNL-Astrostem is administered by intravenous infusion so patients don't have to worry about any invasive and painful surgical procedure. Dr. Jeong Chan Ra, CEO of RNL Bio, said, "Our stem cell therapeutics involves no immune rejection because the stem cells are exactly the patient's own. Our adult stem cell has no tumorigenicity activity at all while embryonic stem cell faces high risk of it. We have developed the safest therapeutics to help devastated patients with incurable diseas

[mickymoose99]

Proton Laboratories, Inc./RegenoBody Announces Delivery of Lab to Sosua Site

Share
retweet
EmailPrint..Companies:Proton Laboratories, Inc..Related Quotes
Symbol Price Change
PLBI.PK 0.01 0.00


{"s" : "plbi.pk","k" : "a00,a50,b00,b60,c10,g00,h00,l10,p20,t10,v00", "o" : "","j" : ""} Press Release Source: Proton Laboratories, Inc. On Monday September 20, 2010, 9:00 am

SOSUA BAY, Dominican Republic, Sept. 20, 2010 (GLOBE NEWSWIRE) -- Proton Laboratories, Inc. (Pink Sheets:PLBI - News) CEO, Armando Casciati, announced today that the clean lab modular system has been released from customs and delivered to the laboratory site across the street from the clinic in a standalone facility. "We expect the lab to be installed and the remaining two pieces of equipment to be delivered by the end of October," stated Mr. Casciati. Mr. Casciati went on to say that "we are taking every precaution to construct this laboratory to the standards needed to safeguard the process of stem cell regeneration and with the supervision of Dr. Lee, we are confident that it will be done properly. Once a patient's fatty tissue stem cells are removed and analyzed, the lab will be the key factor in the regeneration of new stem cells from clients and therefore must be processed in a very clean, secure environment with detailed record keeping and culture identification. The lab will also be the key in new research and development projects that may be presented.



About Proton Laboratories, Inc. and its wholly owned subsidiary RegenoBody S.A:



RegenoBody S.A., a wholly owned subsidiary of Proton Laboratories, Inc., brings the benefits of bioscience to patients who have been diagnosed with chronic debilitating diseases, offering viable, efficient therapeutic options with special Stem Cell Therapies utilizing the most effective cell regeneration techniques. Therapies are tailored for each individual, based upon their specific needs. Cells are obtained by the most modern technologic methods. The transplant physicians and stem cell laboratory scientists, associated with RNL Bio have been regarded as some of the best in the world. Stem cells derived from Autologous (Stem cells taken from your own body) and Allogeneic (Stem cells from a source other than your own) are used depending on the particular condition that needs to be treated. Treatments will be delivered by an experienced team of International and U.S. Board Certified Physicians who are guided by strict protocols ensuring excellence in medical care.



About RNL Bio Company LTD:



RNL Bio is a premier biopharmaceutical company focused on development and commercialization of adult stem cell therapeutics and dog cloning technology. Headquartered in Seoul with state-of-the-art GMP facility, RNL is publicly traded company on the Korea Exchange (Code 003190) and strives to become a global leader across the biomedical industry.

[mickymoose99]

Proton Laboratories, Inc./RegenoBody Sends Dr. David Lee, a World Class Scientist, Together With an Associate MD to South Korea for Special Stem Cell Training, and Protocol Writing

Share
retweet
EmailPrint..Companies:Proton Laboratories, Inc..Related Quotes
Symbol Price Change
PLBI.PK 0.0102 0.0000


{"s" : "plbi.pk","k" : "a00,a50,b00,b60,c10,g00,h00,l10,p20,t10,v00", "o" : "","j" : ""} Press Release Source: Proton Laboratories, Inc. On Tuesday September 21, 2010, 9:00 am

SOSUA BAY, Dominican Republic, Sept. 21, 2010 (GLOBE NEWSWIRE) -- Proton Laboratories, Inc. (Pink Sheets:PLBI - News) CEO, Armando Casciati, announced today that Dr. Keunmyoung David Lee, Ph.D. will complete his training at RNL Bio Ltd. in Seoul South Korea this week. As part of the license agreement with RNL Bio that RegenoBody has, RNL Bio is obligated to provide training for designated personnel. Dr. Lee, who not only has an extensive background in stem cell research, but who also speaks fluent Korean, has spent the last week and will spend part of this week in training and educational instruction on the methodologies and techniques employed by RNL Bio in their laboratory as well as the systems and procedures they use in the cataloging and management of the stem cell cultures. Mr. Casciati went on to say that "with the completion of the training, coupled with the installation of the processing laboratory, our planned opening for business is making great progress. We are very gratified that we are now so close to meeting our planned objective of delivering world class services to needy patients."



Dr. Keunmyoung David Lee, Ph.D. is a widely published and respected research scientist with expertise in the areas of biochemistry, molecular biology and cell biology with a particular focus on Mesenchymal Stem Cell research. He has over 25 years of biotechnology lab experience, including 10 years experience in managing biotechnology company operations. Dr. Lee was critical in the initial laboratory setup and ongoing management of the company where he has worked over the past 8 years. Prior to that, Dr. Lee assisted in launching Rexahn Corporation and served as Director of Discovery Program, initiating and managing R&D in various areas including anti-cancer, anti-viral, bioinformatics and computational biology. Given these positions, along with previous roles he has served--as Senior Scientist at Osiris Therapeutics and as a Post Doctoral Fellow at Case Western Reserve University--Dr. Lee is recognized as one of the leading experts in the most cutting-edge areas of gene therapy, tissue generation and cancer research, specifically with respect to the use of Mesenchymal Stem Cells.



Dr. Lee received his Ph.D. in Genetics at University of California, Riverside, M.S. in Biochemistry at Emory University and B.S. in Chemistry and Education in Seoul National University. He is a member of various professional science and research associations, including NIH CounterACT Network Research Symposium, American Society of Gene Therapy and The Society of Biomedical Research. Dr. Lee has been widely published in peer-reviewed journals and publications, and has delivered numerous scientific orations and seminars, on topics within the scope of gene therapy and cancer research, most notably on his research and publications on Mesenchymal Stem Cells.



About Proton Laboratories, Inc. and its wholly owned subsidiary RegenoBody S.A: RegenoBody S.A., a wholly owned subsidiary of Proton Laboratories, Inc., brings the benefits of bioscience to patients who have been diagnosed with chronic debilitating diseases, offering viable, efficient therapeutic options with special Stem Cell Therapies utilizing the most effective adult stem cells in the world today. Therapies are tailored for each individual, based upon their specific needs. Cells are obtained by the most modern technologic methods. The transplant physicians and stem cell laboratory scientists, associated with RNL Bio have been regarded as some of the best in the world. Stem cells derived from Autologous (Stem cells taken from your own body) and Allogeneic (Stem cells from a source other than your own) are used depending on the particular condition that needs to be treated. Treatments will be delivered by an experienced team of International and U.S. Board Certified Physicians who are guided by strict protocols ensuring excellence in medical care.



About RNL Bio Company LTD:



RNL Bio is a premier biopharmaceutical company focused on development and commercialization of adult stem cell therapeutics and dog cloning technology. Headquartered in Seoul with state-of-the-art GMP facility, RNL is publicly traded company on the Korea Exchange (Code 003190) and strives to become a global leader across the biomedical industry.



FORWARD-LOOKING STATEMENT:

[KentonStocks]

Looking For Winning Stock Information?
Subscribe now to this stock report with exceptional service to guide you!

Just Click this to subscribe